mirabegron / Generic mfg. - LARVOL DELTA

Alfuzosin and Mirabegron for Double-J Stent Symptoms (clinicaltrials.gov) - P=N/A | N=100 | Completed | Sponsor: University of Gaziantep

New trial

Investigating the Adjunctive Use of Mirabegron in the Early Post-Rezum Procedure Period (clinicaltrials.gov) - P3 | N=50 | Not yet recruiting | Sponsor: University of Manitoba

New P3 trial • Benign Prostatic Hyperplasia

Impact of β3-adrenergic receptor agonist on tumor progression and metastasis in renal cell carcinoma models. (PubMed, Cancer Cell Int) - "The β3-AR agonist increases PAT browning, initially promoting primary tumor progression and possibly contributing to tumor initiation, but eventually inducing immune tolerance, leading to anticancer effects on primary tumors. Effects on lung metastases differed from those on primary tumors."

Journal • Genito-urinary Cancer • Immune Modulation • Immunology • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Urology

Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls (clinicaltrials.gov) - P1 | N=48 | Active, not recruiting | Sponsor: The University of Texas Medical Branch, Galveston | Recruiting ➔ Active, not recruiting | Trial completion date: Jul 2025 ➔ Dec 2025 | Trial primary completion date: Jun 2025 ➔ Nov 2025

Enrollment closed • HEOR • Trial completion date • Trial primary completion date • Urinary Incontinence • Urology

EVALUATION OF THE EFFECT OF MIRABEGRON ON BLOOD PRESSURE AND KIDNEY FUNCTION TESTS IN OAK VALE MEDICAL CENTER PATIENTS-LIVERPOOL-UK (ERA 2025) - "Blood pressure and kidney function tests should be monitored before starting treatment with Mirabegron and regularly during treatment, especially in patients with pre-existing hypertension or renal impairment. In addition, Mirabegron should be avoided if systolic BP is above 180 and better not to be given until control Bp."

Clinical • Cardiovascular • Hypertension • Overactive Bladder • Urinary Incontinence

Comparative efficacy and adverse effects of β3-agonists and antimuscarinics in overactive bladder: a network and component network meta-analysis. (PubMed, Eur J Clin Pharmacol) - "β3-agonists, especially vibegron, are effective for OAB symptoms (MF and UUI), both alone and with antimuscarinics. For short-term treatment, combination therapies seem superior to monotherapies in symptom control."

Adverse events • Journal • Retrospective data • Cardiovascular • Constipation • Gastroenterology • Gastrointestinal Disorder • Overactive Bladder • Urinary Incontinence • Urology • Xerostomia

Escitalopram can reverse co-occurring depression and overactive bladder induced by corticosterone in rats. (PubMed, Eur J Pharmacol) - "Escitalopram effectively alleviates both depressive symptoms and bladder dysfunction in a rat model of coexisting depression and OAB. These findings suggest that escitalopram may offer a promising dual-acting therapeutic approach for patients with both conditions. Further studies are required to examine its long-term efficacy and safety in clinical practice."

Journal • Preclinical • CNS Disorders • Depression • Mood Disorders • Overactive Bladder • Psychiatry • Urology

Mirabegron for Cardiac Disease: A New Therapeutic Frontier. (PubMed, Cardiol Rev) - "Future research must prioritize identifying biomarkers predictive of response, evaluating synergy with current therapies, and determining the durability of benefits. Mirabegron represents a promising, mechanistically distinct approach to neurohormonal modulation in HF, with the potential to address gaps unmet by conventional therapies."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Overactive Bladder

Mirabegron Ingestion Enhances Thermal Resiliency And Delays Shivering Onset During Progressive Cold-water Immersion (ACSM 2025) - "MIRA ingestion extended immersion time and increased Tsc, likely contributing to the delayed shivering onset vs PLA. Our findings suggest that MIRA enhances thermal resiliency during a progressive CWI."

Efficacy of Mirabegron and Propiverine Combination in the Treatment of Refractory Overactive Bladder. (PubMed, Int Urogynecol J) - "Mirabegron + propiverine treatment is an effective and reliable treatment option in the treatment of OAB resistant to medical monotherapy. With this combination treatment to be used before botulinum toxin application in the treatment of resistant OAB, the number of patients who will receive Botox may decrease."

Journal • Constipation • Gastroenterology • Gastrointestinal Disorder • Overactive Bladder • Urinary Incontinence • Xerostomia

The Development of Synthetic Routes Leading to Pharmaceuticals and the Key Intermediates Using Hydroxynitrile Lyase. (PubMed, J Org Chem) - "In this investigation, we developed several novel synthetic routes using hydroxynitrile lyase (HNL) from Parafontaria laminata (PlamHNL) to synthesize active pharmaceutical ingredients, specifically Cenobamate (Xcopri), Clopidogrel (Plavix), and Mirabegron (Myrbetriq). Our methods demonstrate higher enantioselectivity, improved regioselectivity, and better yields. Notably, both Xcopri and Clopidogrel are produced from a common intermediate, (R)-methyl-2-chloro mandelate."

Journal

Cutting-edge assays for mirabegron and tadalafil combo therapy for benign prostatic hyperplasia; insilico kinetics approach; multi trait sustainability assessment. (PubMed, BMC Chem) - "Furthermore, artificial intelligence was employed through an online tool to ensure that there were no potential drug-drug interactions between MIR and TAD, offering an additional layer of safety in clinical applications. This research contributes to the enhancement of quality control for patients undergoing combination therapy with MIR and TAD and stability testing."

Journal • Benign Prostatic Hyperplasia • Overactive Bladder

Updated Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the United States (ISPOR 2025) - "Vibegron continues to have modest budget impact to health plans despite introduction of generic mirabegron. Improved outcomes and reduced costs associated with decreased ACB and fewer drug-drug interactions may partially offset increased pharmacy costs."

HEOR • Alzheimer's Disease • Cardiovascular • Cognitive Disorders • Musculoskeletal Diseases • Orthopedics • Overactive Bladder

Drug and behavioral therapy in the treatment of lower urinary tract symptoms that persist after surgical treatment of benign prostatic hyperplasia (PubMed, Urologiia) - "The study demonstrated the high efficiency of behavioral therapy and monotherapy with M-anticholinergic and beta-3-agonist in the treatment of LUTS that persist after surgical treatment of BPH. At the same time, both options of drug therapy demonstrate significantly greater efficiency than behavioral therapy in reducing the severity of LUTS and storage symptoms in particular, as well as in reducing detrusor pressure during its involuntary contractions. Therapy with the beta-3-agonist Mirabegron has a better safety profile than therapy with the M-anticholinergic Solifenacin, which results in greater patient compliance."

Clinical • Journal • Benign Prostatic Hyperplasia • CNS Disorders

Combined use of mirabegron and solifenacin: new standards for successful treatment of overactive bladder (PubMed, Urologiia) - "The aim of this review was to analyze the combined use of mirabegron (3-adrenergic agonist) and solifenacin (M-anticholinergic or muscarinic receptor antagonist), focusing on clinical trials, safety issues, and practical aspects. The combination therapy showed superior efficacy compared to monotherapy and an acceptable safety profile, making it a viable treatment strategy for patients with OAB who do not achieve optimal outcomes with a monotherapy."

Journal • Review • Overactive Bladder • Urinary Incontinence • Urology

A comparative study of mirabegron versus doxazosin in improving ureteral stent-related dysfunction. (PubMed, World J Urol) - P4 | "Mirabegron and doxazosin demonstrated similar efficacy in relieving ureteral stent-related symptoms. However, mirabegron offered a clear advantage in improving female sexual function, particularly regarding pain during intercourse and overall satisfaction."

Clinical • Journal • Pain • Sexual Disorders

Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity (clinicaltrials.gov) - P4 | N=300 | Recruiting | Sponsor: Mackay Memorial Hospital | Trial completion date: Jun 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2024 ➔ Jun 2026

Trial completion date • Trial primary completion date

Impact of β3-adrenergic receptor agonist on kidney cancer risk in patients with overactive bladder. (PubMed, BJU Int) - "Use of β3-AR agonists was associated with an increased risk of kidney cancer compared with anticholinergics. While these findings suggest a potential association between mirabegron use and kidney cancer, further studies are needed to confirm causality. Clinicians should exercise caution when prescribing mirabegron in patients with risk factors for kidney cancer."

Journal • Genito-urinary Cancer • Kidney Cancer • Oncology • Overactive Bladder • Renal Cell Carcinoma • Solid Tumor

Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity (clinicaltrials.gov) - P4 | N=200 | Recruiting | Sponsor: Mackay Memorial Hospital | N=100 ➔ 200 | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Jun 2025 ➔ Jun 2026

Enrollment change • Trial completion date • Trial primary completion date

Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder (clinicaltrials.gov) - P4 | N=300 | Recruiting | Sponsor: Mackay Memorial Hospital | Trial completion date: Jun 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2024 ➔ Jun 2026

Trial completion date • Trial primary completion date • Overactive Bladder

A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity (clinicaltrials.gov) - P3 | N=10 | Recruiting | Sponsor: Astellas Pharma Global Development, Inc. | Trial completion date: Jun 2026 ➔ Sep 2026 | Trial primary completion date: Feb 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date

Mirabegron induces selective changes in the faecal microbiota of HFHFr rats without altering bile acid composition. (PubMed, Front Pharmacol) - "Furthermore, mirabegron treatment changes the relative abundance of several genus and families of rat faecal microbiota, albeit without restoring the global biodiversity and evenness indexes observed in control rats, as well as faecal bile acids composition. These changes are probably due to a direct effect of mirabegron on the gut microbiome, rather than being mediated by changes in bile acid induced by drug treatment."

Journal • Preclinical • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Overactive Bladder

Assessment of efficacy of mirabegron, solifenacin, tadalafil 5 mg and combination therapy in female patients with overactive bladder: a double blinded multicenter prospective placebo-controlled trial. (PubMed, Minerva Urol Nephrol) - "The novel combination therapies of tadalafil 5mg with solifenacin or mirabegron are more effective in reducing OAB symptoms and improving urodynamic parameters compared to single-agent therapies and placebo. These findings suggest that combination therapy is alternative pathway which can enhance outcomes for female patients with OAB. Further research is warranted to validate these results and explore long-term efficacy and safety."

Journal • Overactive Bladder

National Trends in Medication Prescriptions for Male Lower Urinary Tract Symptoms and Erectile Dysfunction: Findings from the Norwegian Prescription Database. (PubMed, Eur Urol Open Sci) - "Sildenafil was the most popular choice (47%), followed by tadalafil (43%) and vardenafil (4.8%); the number of users per 1000 men increased from 4.4 to 9.3. Among medications used for urinary incontinence/urgency, mirabegron was the most popular choice (62%) in 2020, followed by oxybutynin (17%)...The biggest rise was for medications for BPE, which are now prescribed more often than for medications for erectile dysfunction. In recent years, the number of surgeries performed for BPE has fallen."

Journal • Benign Prostatic Hyperplasia • Erectile Dysfunction • Urinary Incontinence • Urology

Colon-Targeted β3-Adrenoceptor Agonist Mirabegron Enhances Anticolitic Potency of the Drug via Potentiating the Nrf2-HO-1 Pathway. (PubMed, Mol Pharm) - "MAS-Glu was therapeutically superior to sulfasalazine, a current drug to treat inflammatory bowel disease, against rat colitis. Moreover, MBG activated the anti-inflammatory nuclear factor erythroid 2-related factor 2 (Nrf2)-hemeoxygenase (HO)-1 pathway in inflamed colonic tissue, and the MAS-Glu-mediated amelioration of colitis was significantly compromised by an HO-1 inhibitor. Taken together, colon-targeted delivery of MBG may enhance the anticolitic activity, reduce the risk of systemic side effects of MBG, and elicit the therapeutic effects, at least partly by activating the Nrf2-HO-1 pathway."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Overactive Bladder